Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Do you recommend consolidation immunotherapy after SBRT or surgery and chemo for T1-T2N0 SCLC?
Related Questions
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
Would you give lung SBRT to a patient with bullous pemphigoid on the chest and torso?
Do more fractionated regimens reduce severe toxicity over SBRT in patients with ILD and early-stage NSCLC?
Do you offer adjuvant durvalumab for stage I small cell lung cancer following SBRT or surgery?
how do you manage atypical adenomatous hyperplasia (AAH) at the margin for 2 sites of the same lobe, in a patient with multiple GGO's s/p wedge resection?
Is there any role for adjuvant radiotherapy for resected multistation N2 atypical carcinoid tumor of the lung?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
What are your top takeaways in Thoracic Cancers from ASTRO 2024?
